

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box PCT, Commissioner for Patents, Washington, D.C. 20231 on 4/16/02.

By:  Printed: Margaret M. Hasson

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Tang et al.

Title: HUMAN HYDROLASE PROTEINS

Serial No.: 09/831,455

Filing Date: To Be Assigned

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

---

Box PCT  
Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE  
AND AMENDMENT DIRECTING ENTRY INTO THE SPECIFICATION**

Sir:

This paper is in response to the Notification of Defective Response mailed on April 2, 2002 for which a response is due on May 2, 2002.

Applicants submit this amendment to request entry of the enclosed paper copy of the sequence listing from International Application Number PCT/US99/27099 into the above-identified U.S. national phase patent application.

Applicant(s) submit the document(s) listed below to complete the filing for the above-identified patent application.

1. A Substitute Computer Readable Form (CRF) of the "Sequence Listing" of the above-identified USN application;
2. Submission Under 37 CFR § 1.821 - 1.825 Sequence Listing (1 pg.);
3. A substitute paper copy of the "Sequence Listing" (30 pp.);
4. A copy of PTO form PCT/DO/EO/916 (371 Formalities Notice); and
5. A return receipt postcard.


In the Notification, the Office of Initial Patent Examination has requested a replacement sequence listing and an amendment directing its entry into the specification – where it already exists and has since the initial PCT filing. These actions are not understood.

Applicant's do not believe a fee is due with this filing. However, if the Patent Office deems that a fee is due, please charge Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,  
INCYTE GENOMICS, INC.

Date: 15 April 2002



Diana Hamlet-Cox  
Reg. No. 33,302  
Direct Dial Telephone: (650) 845-4639

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886

APR - 9 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 101  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/831,455	Tom Y Tang	PF-0634 USN

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/US99/27099

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

11/12/1999

11/12/1998

Incyte Genomics  
3160 Porter Drive  
Palo Alto, CA 94304

CONFIRMATION NO. 4335

371 FORMALITIES LETTER



\*OC00000007755135\*

*RESP/2/02*

Date Mailed: 04/02/2002

### NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
  - See attached CRF Problem Report.
  - APPLICANT MUST PROVIDE:
    - An initial or substitute computer readable form (CRF) of the "Sequence Listing."

- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
    - For Rules Interpretation, call (703) 308-4216
    - To Purchase PatentIn Software, call (703) 306-2600
    - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
  - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/831,455	PCT/US99/27099	PF-0634 USN